Pharvaris N.V., a late-stage biopharmaceutical company, has announced the successful closing of its upsized public offering, which raised approximately $201.2 million in gross proceeds. The offering included 9,562,500 ordinary shares and pre-funded warrants to purchase 500,000 ordinary shares, with the underwriters exercising their option to purchase an additional 1,312,500 ordinary shares in full. The offering was managed by Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen as joint book-running managers. The proceeds from this offering are expected to support Pharvaris's continued development of novel treatments for bradykinin-mediated diseases, such as hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency.